rss
J Med Genet 2009;46:418-420 doi:10.1136/jmg.2008.064212
  • Mutation report

Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome

  1. C P Kratz1,
  2. S Holter2,
  3. J Etzler3,
  4. M Lauten1,
  5. A Pollett2,
  6. C M Niemeyer1,
  7. S Gallinger2,
  8. K Wimmer3,4
  1. 1
    Department of Pediatrics and Adolescent Medicine, Pediatric Hematology/Oncology, University of Freiburg, Freiburg, Germany
  2. 2
    Dr Zane Cohen Digestive Diseases Clinical Research Centre, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, Ontario, Canada
  3. 3
    Department of Medical Genetics, Medical University of Vienna, Vienna, Austria
  4. 4
    Division of Clinical Genetics, Medical University Innsbruck, Innsbruck, Austria
  1. Dr K Wimmer, Division of Clinical Genetics, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University Innsbruck, Schoepfstr. 41, 6020 Innsbruck, Austria; katharina.wimmer{at}i-med.ac.at
  • Received 2 December 2008
  • Revised 28 January 2009
  • Accepted 6 February 2009
  • Published Online First 16 March 2009

Abstract

Background: Biallelic germline mutations in the mismatch repair genes MLH1, MSH2, MSH6 or PMS2 cause a recessive childhood cancer syndrome characterised by early-onset malignancies and signs reminiscent of neurofibromatosis type 1 (NF1). Alluding to the underlying genetic defect, we refer to this syndrome as constitutional mismatch repair-deficiency (CMMR-D) syndrome. The tumour spectrum of CMMR-D syndrome includes haematological neoplasias, brain tumours and Lynch syndrome-associated tumours. Other tumours, such as neuroblastoma, Wilm tumour, ovarian neuroectodermal tumour or infantile myofibromatosis, have so far been found only in individual cases.

Results: We analysed two consanguineous families that had members with suspected CMMR-D syndrome who developed rhabdomyosarcoma among other neoplasias. In the first family, we identified a pathogenic PMS2 mutation for which the affected patient was homozygous. In family 2, immunohistochemistry analysis showed isolated loss of PMS2 expression in all tumours in the affected patients, including rhabdomyosarcoma itself and the surrounding normal tissue. Together with the family history and microsatellite instability observed in one tumour this strongly suggests an underlying PMS2 alteration in family 2 also.

Conclusion: Together, these two new cases show that rhabdomyosarcoma and possibly other embryonic tumours, such as neuroblastoma and Wilm tumour, belong to the tumour spectrum of CMMR-D syndrome. Given the clinical overlap of CMMR-D syndrome with NF1, we suggest careful examination of the family history in patients with embryonic tumours and signs of NF1 as well as analysis of the tumours for loss of one of the mismatch repair genes and microsatellite instability. Subsequent mutation analysis will lead to a definitive diagnosis of the underlying disorder.

Footnotes

  • Competing interests: None.

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JMG.
View free sample issue >>

Free archive
The full back archive is now available for JMG. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest genetics jobs

    Latest genetics jobs